VTCN1 and breast cancer: Furthermore, our data indicated that neutralizing antibody against B7-H4 significantly decreased tumor cell viability in vitro, and the protein confers resistance to doxorubicin by reducing the sensitivity of breast cancer cells to apoptosis, mediated via the PTEN/PI3K/Akt pathway.